墨西哥八个次区域HIV-1一线ART启动前耐药调查
2017年9月至2018年3月在墨西哥八个次区域开展具次国家代表性的HIV治疗前耐药(PDR)调查,纳入2006名来自74家诊所的初治及既往暴露者。结果显示NNRTI类PDR高于其他药物类别(P<0.0001),东北、东部、西南和东南四个次区域超过10%阈值;女性任何药物PDR高于男性(16.5%对12.2%,P=0.04)。
要点
- NNRTI类PDR高于其他药物类别,四个次区域超过10%阈值
- 西南部NNRTI PDR较高(P=0.02),该区重启治疗者比例最高(14%)
- 女性任何药物PDR高于男性(16.5%对12.2%,P=0.04)
核心结论
- 墨西哥HIV治疗前NNRTI耐药高于其他药物类别,且在东北、东部、西南和东南四个次区域超过10%阈值。
- NNRTI PDR升高与既往抗逆转录病毒暴露及欠发达地区相关,提示可基于次区域特征调整公共卫生应对。
- 基因网络分析显示按次区域高度聚集(P<0.0001),存在本地簇内耐药突变传播证据。
研究设计与样本
- 2017年9月至2018年3月在墨西哥八个次区域开展治疗前耐药调查,纳入所有较大诊所(覆盖90%的ART启动者)。
- 采用概率比例规模法分配样本量,共从74家诊所纳入2006名参与者,含初治与既往暴露者。
- PDR水平基于WHO指定实验室获得的pol Sanger序列估算。
主要发现
- NNRTI类PDR高于其他药物类别(P<0.0001),在东北、东部、西南和东南超过10%阈值。
- 西南部NNRTI PDR较高(P=0.02),该次区域重启治疗者比例最高(14%)。
- 女性任何药物PDR高于男性(16.5%对12.2%,P=0.04)。
- 多因素调整后,既往抗逆转录病毒暴露与NNRTI PDR升高在中北部、西北部、西南部和东南部仍显著相关(aOR分别为21、5、8和25,P<0.05)。
临床怎么用
- 可考虑依据次区域特征对HIV耐药公共卫生应对进行差异化调整。
- NNRTI PDR较高与欠发达地区相关,提示有机会加强当地HIV项目。
- 有必要就含整合酶抑制剂的治疗方案开展价格与许可谈判。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: HIV pretreatment drug resistance (PDR) to NNRTIs in persons initiating ART is increasing in Mexico. OBJECTIVES: To compare HIV PDR in eight sub-regions of Mexico. PATIENTS AND METHODS: A large PDR survey was implemented in Mexico (September 2017-March 2018) across eight sub-regions. All larger clinics (which provide ART to 90% of all initiators) were included, allocating sample size using the probability-proportional-to-size method. Both antiretroviral-naive and prior antiretroviral-exposed persons were included. HIV PDR levels were estimated from pol Sanger sequences obtained at a WHO-designated laboratory. RESULTS: A total of 2006 participants were enrolled from 74 clinics. PDR to NNRTIs was higher than to other drug classes (P < 0.0001), crossing the 10% threshold in the North-East, East, South-West and South-East. NNRTI PDR was higher in the South-West (P = 0.02), coinciding with the highest proportion of restarters in this sub-region (14%). We observed higher PDR prevalence to any drug in women compared with men (16.5% versus 12.2%, P = 0.04). After multivariable adjustment, higher NNRTI PDR remained significantly associated with previous antiretroviral exposure in the Centre-North, North-West, South-West and South-East [adjusted OR (aOR): 21, 5, 8 and 25, respectively; P < 0.05]. Genetic network analyses showed high assortativity by sub-region (P < 0.0001), with evidence of drug resistance mutation transmission within local clusters. CONCLUSIONS: Diversification of the public health response to HIV drug resistance based on sub-regional characteristics could be considered in Mexico. Higher NNRTI PDR levels were associated with poorer regions, suggesting opportunities to strengthen local HIV programmes. Price and licensing negotiations of drug regimens containing integrase inhibitors are warranted.
引用
- Ávila-Ríos S, García-Morales C, Valenzuela-Lara M, et al. HIV-1 drug resistance before initiation or re-initiation of first-line ART in eight regions of Mexico: a sub-nationally representative survey. J Antimicrob Chemother. 2019. PMID: 30597094. doi:10.1093/jac/dky512
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。